Sun Pharma shares dip 4%, m-cap drops by Rs 5,065 cr as Q2 net declines 59%

The scrip was the worst hit among the 30 Sensex blue chips

Sun Pharma shares dip 4%;
A logo of Sun Pharmaceutical Industries Ltd is pictured at its research and development centre in Mumbai (Photo: Reuters)
Press Trust of India New Delhi
Last Updated : Nov 15 2017 | 4:32 PM IST
Shares of Sun Pharmaceutical Industries on Wednesday ended 4 per cent lower after the company reported a 59.19 per cent decline in consolidated net profit for the September quarter of the current financial year.

The stock slipped 4.01 per cent to end at Rs 505.05 on BSE. During the day, it lost 4.76 per cent to Rs 501.10.

The scrip was the worst hit among the 30 Sensex blue chips.

Also Read

On NSE, shares of the company dipped 4 per cent to close at Rs 504.65.

The company's market valuation also fell by Rs 5,064.97 crore to Rs 1,21,174.03 crore.

In terms of equity volume, 10,32,000 shares of the company were traded on BSE and over 86 lakh shares changed hands on NSE during the day.

Pharma major Sun Pharmaceutical Industries yesterday reported a 59.19 per cent drop in consolidated net profit to Rs 912.12 crore for the September quarter, mainly on account of degrowth in the US sales.

The company had posted a net profit of Rs 2,235.14 crore for the corresponding period of the previous fiscal, Sun Pharma said in a BSE filing.

Consolidated total revenue from operations stood at Rs 6,650.34 crore. It was Rs 8,260.11 crore in the same period of the previous year.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Nov 15 2017 | 4:23 PM IST

Next Story